## **CAMBRIDGE EYE TRUST**
## **Report and Accounts October 2023**
|**Contents**||
|---|---|
||**Page**|
|Report of the trustees|1 to 4|
|Statement of financial activities|5|
|Cash flow statement|6|
|Balance sheet|7|
|Notes|8|
|Examiner’s report to the|9|
|trustees||
Cambridge Eye Trust
Web address
## **Trustees' Annual Report**
The trustees present their report for the year to 31st October 2023.
## **Objectives and activities of the charity**
The object of the Cambridge Eye Trust, as set out in its governing document, is to advance the education of the public in the science of ophthalmology, in particular but without limitation by: -
1. i. establishing and maintaining the Cambridge Ophthalmological Symposium (to be held periodically and to be open to specialists or students of Ophthalmology or related sciences), for the study, discussion and reading of papers on topics related to the science and practical development of Ophthalmology and all allied subjects; including the provision of lecturers and other speakers for the Symposium and the publication of reports of the proceedings; and
- ii. supporting the research of lecturers and researchers in the field of Ophthalmology.
The advancement of research and education of the public in the science of ophthalmology is achieved by:-
- 1 Facilitating the interaction between science and medicine, by hosting the annual Cambridge Ophthalmological Symposium. The Symposium held in September 2023 was on “Engineering and the Eye”, chaired by a distinguished medical ophthalmologist and a Professor of Engineering at Cambridge. In 2024, the Symposium will be held on ‘Evolution and the Eye’ chaired by an academic Ophthalmic Veterinary Surgeon.
- 2 Offering bursaries to junior scientists, doctors in training and PhD students, who are actively involved in the subject under discussion but who cannot afford to attend the symposium, even though this would be valuable for their research.
- 3 Supporting clinical and laboratory scientific research in ophthalmology, particularly in the areas of glaucoma and optic nerve diseases, corneal and strabismus surgery and the genetics and management of Stickler’s Syndrome. These aspects are represented by acknowledged experts in the field, who are Consultants in the Eye Department of Addenbrooke’s Hospital in Cambridge. A major effort in basic science research has been aimed at protecting and repairing the damaged optic nerve. This support has provided bridging finance for staff between grants, as well as, occasionally, providing staff for limited periods and from time to time providing essential equipment and materials, which cannot be obtained in other ways.
- 4 Publication of contributions to the Symposium in “Eye’ the Journal of the Royal College of Ophthalmology.
- 5 Supporting initiatives for the ophthalmologists in training at Addenbrooke's Hospital Cambridge, for example in providing support for simulator training in ophthalmic surgery, and promoting research days for the trainees in the region
**Cambridge Eye Trust**
Page 1
- 6 Promoting research in the science of vision to ophthalmologists in training, A level students and medical students, by supporting travel grants to science conferences or student electives in ophthalmology.
- 7 Publishing a Newsletter and maintaining a website. Information about ophthalmological topics is included on the charity's website and in a regular newsletter, both are freely available to the public and ophthalmologists. The Cambridge Eye Trust newsletter continued in 2023.
## **Achievements and performance**
The trustees continued to support the programme of research set up in September 2017 in the Centre for Brain Repair by Professor Keith Martin, who moved in 2019 to Melbourne Australia to head the Centre for Eye Research Australia. This programme ‘Enhancement of Optic Nerve Regeneration by modulation of Integrins’ aims to promote orderly and controlled regeneration of axons in the optic nerve without reliance on oncogenes, offering hope of restoring vision to those blind with optic nerve disease. The Trust continued the funding in 2023, allowing two PhD students to complete their research work in Cambridge and supporting a previous member of the team, who is currently working in clinical ophthalmology and basic science research in this field in the USA.
In 2020, the Trustees received a request from Patrick Yu Wai Man, Professor of Ophthalmology at the University of Cambridge, for an OCT (Optical Coherence Tomography) machine to use in a dedicated eye research facility, in order to study patients undergoing a research trial of gene therapy for Leber’s Hereditary Optic Neuropathy. After due consideration, the Trust granted a sum of £50,000 to purchase the OCT for the research room. The equipment is also available for other research trials conducted by other members of the Addenbrooke’s Eye Department. OCT is a non-invasive diagnostic instrument used for imaging the retina. The OCT uses an array of light to scan rapidly the eye. These scans are interpreted by the software in the machine and the OCT then presents an image of the tissue layers within the retina. This new diagnostic facility is now widely used in the diagnosis and management of many ocular conditions. The OCT machine is employed in two on-going research studies of gene therapy injections into the eye for optic nerve diseases, conducted by Professor Man.
The Trust also supported a study of the genetic make-up of the cells forming the posterior layer of the vitreous, planned by a team under the supervision of Martin Snead, Director of Vitreo-Retinal Research at Cambridge. Posterior vitreous detachment remains poorly understood. Although the condition is usually a benign event, a significant minority of patients will experience sight-threatening conditions shortly after the detachment of posterior vitreous. The study aims to characterise the gene expression profiles of individual cells and to establish whether there are characteristics which may distinguish pathological from physiological outcomes.
## **Plans for the future**
If new advances are to be made within the field of medical ophthalmology it is vital that clinician scientists are trained in research in this specialty.
This is one of the long-term aims of the charity and the generous funding provided by the Dickerson Fellowship has enabled the Trust to support a joint post-doctorate research post, to work in the current research programme of the University of Cambridge and the
**Cambridge Eye Trust**
Page 2
Ophthalmic Department of Addenbrooke’s NHS Trust.
The Trust guaranteed to support a new post of Senior Clinical Research Associate and in June 2023 the Trust was delighted that a joint appointment between the University of Cambridge, Addenbrooke’s and Addenbrooke’s NHS Trust was made for an individual, who will start in January 2025.
## **Organisation**
The affairs of the charity are conducted by the trustees with the assistance of a freelance conference organiser and a financial adviser (who maintains accounting records and prepares periodic accounts). There are no volunteers apart from the trustees.
The trustees serving in the year and the subsequent period to date were: -
Mr N J Sarkies Mr R Ashby- Johnson Mr Douglas Newman Chairman Professor M Rajan Mr C René Mrs H Shahid
New trustees are selected according to the perceived needs of the charity.
## **Legal and administrative information**
The trust maintains a website for which the address is www.cambridgeeyetrust.org.uk
Cambridge Eye Trust is a charitable trust registered with the Charity Commission for England and Wales under reference 265140.
The governing document is a Scheme dated 16th November 2004. The trustees are incorporated as -
‘The Incorporated Trustees of The Cambridge Ophthalmological Symposium’ so that investments may be held in that name. The principal address for correspondence is:
Wistow, The Green, Hilton, Huntingdon, Cambridgeshire PE28 9NB
Monies are held at CAF Bank Ltd and on deposit with the Charities Official Investment Fund. Some investments are managed by Evelyn Partners Group Ltd of 45 Gresham Street, London EC2V 7BG, an independent adviser authorised and regulated by the Financial Conduct Authority. Investments are held by Evelyn Partners Investment Services Ltd. Other investments have been made in charity authorised investment funds, that are managed for charity investment and as such enjoy advantages. These funds are held directly.
## **Review of financial affairs**
The result for the year to 31[st ] October 2023 was a surplus of £17,852 before a deficit of £14,993 on investments realised and unrealised in the year, as markets deteriorated due to the aftermath of the pandemic and invasion of Ukraine leading to inflation and increased interest rates. The combined surplus was £2,859.
The Symposium had income of some £41,000 which was less than the costs of £51,800. Donations and Gift Aid fell to £6,873 (last year £9,600). Investment income rose by £6,840 to £52,450.
The surplus includes expenditure of £24,297 (last year £7,875) for grants to support research projects and to cover four bursaries for attending the symposium.
**Cambridge Eye Trust**
Page 3
They shall support applications that are received for research projects, and bursaries, subject to their approval. Requests for funding are sent for peer review before being evaluated by the trustees.
The net assets of the trust were £1,673,000 at the October year-end of which £1,574,000 was held in listed investments.
## **Policies**
## **Investment**
The policy of the Trustees is to invest over a long term to provide a total return (being income and capital appreciation combined) that increases over a three-to-five-year period in line with global indices for equity, commercial property and bond investments. It is recognised that the actual returns are likely to be below the index returns, due to management costs and the selection of investments that should mitigate risks. The investments are held in managed funds and investment trusts to achieve both spread and diversity.
The charity does not invest directly in listed companies, and so relies on fund managers to apply ethical investment constraints, which are expected to exclude such as tobacco and gambling activities.
## **Reserves**
The Trustees require reserves sufficient to cover potential deficits from the annual symposium. Any surpluses are accumulated towards supporting educational and research posts for ophthalmologists within the School of Clinical Medicine and for other costs and equipment for research projects.
## **Public benefit**
The trustees have had regard to the guidance on public benefit.
People worldwide with eye problems have benefited directly from advances in medical procedures and instrumentation, discussed during the annual symposia, and from the research associations resulting from contacts made during the residential symposia meetings. Publication of the proceedings extends the knowledge of clinicians throughout the world. Patients will be reassured by reading the information on the Charity’s website and otherwise published, about the procedures that are likely to be applied to them.
If the current research is successful, patients will benefit through the ability of clinicians to prevent detachment of the retina and, if they cannot be prevented, to intervene early in glaucoma, optic nerve, corneal and macular degenerative diseases. In the longer term the aim is to reverse the disease process.
N J C Sarkies. Chairman Cambridge Eye Trust 28[th] December 2023
**Cambridge Eye Trust**
Page 4
**STATEMENT OF FINANCIAL ACTIVITIES Year to 31 October 2023**
||Year to 31 October 2023|Year to 31 October 2023|Year to 31 October 2022|Year to 31 October 2022|
|---|---|---|---|---|
||**Note**|**Unrestr-**|**Note**|**Unrestr-**|
|||**icted fund**||**icted fund**|
|||**£**||**£**|
|**Income from:**|||||
|Donations including Gift Aid||6,873||9,599|
|Charitable activities:|||||
|Registration fees||31,395||57,463|
|Sponsorship and grant||10,120||9,000|
|Investments||52,454||45,611|
|Total income||100,841||121,674|
|**Expenditure on:**|||||
|Charitable activities:|||||
|Costs of the symposium||51,802||66,549|
|Bursaries and grants||930||1,395|
|Research instruments and grants||23,367||7,875|
|Other- investment management and accountancy||6,890||10,906|
|Total expenditure||82,989||86,725|
|||17,852||34,949|
|Net gains or (deficits) on investment assets:|**2**|(14,993)|**2**|(95,411)|
|**Net income**||2,859||(60,462)|
|**Reconciliation of fund**|||||
|Total fund balance brought forward||1,669,359||1,729,821|
|Total fund balance carried forward||1,672,218||1,669,359|
**Cambridge Eye Trust**
Page 5
Printed 09/05/2024
**CASH FLOW STATEMENT Year to 31 October 2023**
|**Note**
**Reconciliation of net income to**
**net cash flow from operating activities**
**Net income or (deficit)**
_Adjustments for:_
Deficits on investment assets
**1**
Dividends and interest from investments
Decrease or (Increaase) in debtors
Decrease or (Increase) in tax recoverable
Increase or (Decrease) in creditors
Net cash provided by operating activities
**Statement of cash flows**
Net cash provided by operating activities as above
_Cash flows from investing activities:_
Dividends and interest from investments
Sales less purchases of investments plus fees
Increase in cash
Bank and deposit balances at start of year
Bank and deposit balances at end of year
**Held as follows**
Evelyn Partners deposit
COIF Charities Deposit Fund
PayPal balance
Bank balance|**2023**
**2022**
**£**
**£**
2,859
(60,462)
14,993
95,411
52,454
45,607
3,371
(3,507)
472
(200)
136
(2,396)|
|---|---|
||74,285
74,453|
||74,285
74,453
(52,454)
(45,607)
3,412
6,304|
||25,243
35,150
80,304
45,154|
||105,547
80,304|
||10,707
10,729
89,998
58,882
-
-
4,842
10,693|
||105,547
80,304|
**Cambridge Eye Trust**
Printed 09/05/2024
Page 6
**BALANCE SHEET As at 31 October 2023**
|**BALANCE SHEET**
**As at 31 October 2023**|||
|---|---|---|
||**31st October 2023**
**31st October 2022**||
|**Note**
**£**
**£**
**£**
**£**
**Investments**
Listed investments per note
**2**
1,574,480
1,592,884
Evelyn Partners deposit
10,707
10,729
COIF Charities Deposit Fund
89,998
58,882
1,675,185
1,662,495
**Current assets**
Debtors and prepayments
135
3,507
Tax recoverable
178
650
PayPal balance
-
-
Bank balance
4,842
10,693
5,155
14,849
**Current liabilities**
Creditors and accruals
6,890
6,754
**Net current assets (liabilities)**
(1,735)
8,096
**Net assets**
1,673,450
1,670,591
**Accumulated fund**
Closing balance
1,672,218
1,669,359
**Endowment**
uOpening and closing balance
1,232
1,232
there being no movements in the year
1,673,450
1,670,591
Approved by the Trustees on 11 December 2023 and signed on their behalf by|||
|||1,670,591|
|||1,669,359
1,232|
|||1,670,591|
||||
|Trustee|||
Trustee
N J C Sarkies
**Cambridge Eye Trust**
Printed 09/05/2024
Page 7
## **NOTES TO THE ACCOUNTS**
## **1 Accounting policies**
- **a)** These accounts have been prepared:-
under the historical cost convention, with the exception of investments which are included at market value, to accord with the Statement of Recommended Practice :
Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) and with the Charites Act 2011.
- b) Investment gains and losses include realised gains and losses on the sale of investments and gains or losses resulting from revaluing investments to market value at the end of the year.
- **c)** Small differences may arise in totals due to rounding pence to whole numbers.
## **2 Listed investments**
|**Listed investments**||
|---|---|
|Opening market value
Sales
Purchases and accumulated dividends less equalisation receipts
Surpluses and deficits on sales in the year
Unrealised surplus arising in the year
Closing valuation|**This year**
**Last year**
1,592,884
1,694,662
(181,876)
(42,710)
178,464
36,343
6,304
(635)
(21,297)
(94,776)|
||1,574,480
1,592,884|
These investments comprise unit and investment trusts and Charity Authorised Investment Funds.
## **3 Payments to trustees**
No remuneration was paid for the year to trustees or to persons known to be connected with any of them.
**Cambridge Eye Trust**
Printed 09/05/2024
Page 8
**Independent Examiner's Report on the Accounts**
## **Report to the Trustees of the Cambridge Eye Trust on accounts for the year to 31st October 2023, as set out on pages 5 to 8.**
As the charity's trustees you are responsible for preparing the accounts; you consider that an audit is not required for this year under section 144 of the Charities Act 2011 ("the Charities Act") and that an independent examination is needed.
It is my responsibility to:-
- examine the accounts under section 145 of the Charities Act,
- follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and
- state whether particular matters have come to my attention.
My examination was carried out in accordance with the General Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.
In connection with my examination, no matter came to my attention:
1. which gives me reasonable cause to believe that in any material respect the requirements to:
- keep accounting records in accordance with section 130 of the Charities Act; and
- prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act
have not been met; or
2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.
Stuart Berriman (Independent Examiner) BFP FCA FCCA Chater Allan LLP 7 Quy Court, Colliers Lane Stow-cum-Quy Cambridge, CB25 9AU
> Date: 9 May 2024
**Cambridge Eye Trust**
_Printed 09/05/2024_
Page 9
## **Year to 31 October 2023**
|**INVESTMENTS**|**Investments held at**|**Investments held at**|**31 October**|**2022**|**Purchases**|**and sales**|**Resulting**|**gains and**|**losses**||**Investments held at**|**Investments held at**|**31 October**|**2023**|**Unrealised**|**surplus**|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**Funds and Unit Trusts**|Holding|Book|Bid|Market|Holding|Cost or|Gain or|Prior|This||Holding|Book|Bid|Market|Prior|This|
|||value|price|value||(proceeds)|loss|years|year|||value|price|value|years|year|
|CG Portfolio Fund Plc Absolute Return|||||||||||||||||
|M distribution units|214|30,101|£136.83|29,246|214|(28,857)|(1,243)|(855)|(389)||||||||
|Continental European Income||||||||||||||||3%|
|D units|11,399|18,646|£1.62|18,491|||||||11,399|18,646|£1.67|19,068|(155)|577|
|Evenlode Income||||||||||||||||2%|
|D income|17,225|29,921|£2.37|40,801|||||||17,225|29,921|£2.40|41,416|10,880|615|
|Evenlode Global Income||||||||||||||||1%|
|F Dis|24,868|29,983|£1.37|34,035|||||||24,868|29,983|£1.39|34,485|4,052|450|
|Fidelity Global Dividend||||||||||||||||3%|
|R income nav|20,399|36,732|£2.14|43,571|24,048||||||44,447|36,732|£1.01|44,758|6,839|1,187|
|Findlay Park American Sterling||||||||||||||||4%|
|I accumulation|333|30,293|£136.00|45,318|||||||333|30,293|£141.96|47,304|15,025|1,986|
|Fundsmith Equity I instl|||||acc divs|123||||||||||7%|
|acc nav|6,589|25,632|£5.68|37,404|1,622|(10,304)|3,995|2,897|1,098||4,967|19,416|£6.12|30,399|8,874|2,078|
|Graham Macro ucits||||||||||||||||1%|
|H platform|||||131|16,064|||||131|16,064|£123.59|16,165||101|
|Guardcap Global Equity|||||||||||||||||
|I Gbp income|3,183|38,100|£13.57|43,200|3,183||||||||||||
|T Gbp income- reconstruction|||||1,512||||||||||||
|T Gbp income|||||1,481|(15,042)|3,024|1,609|1,416||3,214|26,083|£10.12|32,517|3,491|2,944|
|Guinness Global Equity||||||||||||||||-2%|
|Z Global income|||||482|13,052|||||482|13,052|£26.51|12,780||(272)|
|International Public Partnerships||||||||||||||||-16%|
|stock 0.01p|3,840|6,155|£1.56|5,983|7,024|9,086|||||10,864|15,241|£1.16|12,624|(172)|(2,445)|
|Insight Global Funds II|||||||||||||||||
|Libor plus B|13,987|14,732|£1.32|18,532|13,987|(19,351)|4,619|3,800||819|||||||
|Invesco Physical Gold Lkd|||||||-|-||-||||||15%|
|unts|226|24,824|£138.01|31,190|||||||226|24,824|£158.35|35,787|6,366|4,597|
|Japanese W6- Baillie Gifford||||||||||||||||-2%|
|Dis|1,106|19,501|£14.41|15,939|||||||1,106|19,501|£14.06|15,552|(3,562)|(387)|
|Link Fund - Trojan Income|||||||||||||||||
|X income nav|20,640|22,034|£1.23|25,401|20,640|(25,807)|3,774|3,367||406|||||||
|Link Fund - Trojan Income||||||||||||||||-2%|
|X income nav|42,740|44,522|£0.89|38,197|||||||42,740|44,522|£0.88|37,470|(6,325)|(727)|
|Lyxor Core US Tips||||||||||||||||-3%|
|D|||||118|12,000|||||118|12,000|£99.08|11,691|-|(308)|
|M&G UK inflation linked corporate||||||||||||||||0%|
|accumulation|||||16,377|18,072|||||16,377|18,072
,|£1.10|18,049|-|(23)|
|Marshall Wace Developed Europe Tops||||||||||||||||0%|
|G nav|144|16,309|£192.83|27,776|58|(11,092)|4,563|4,590||(27)|86|9,780|£193.93|16,752|6,877|95|
**Cambridge Eye Trust**
Printed 09/05/2024
Page 10
## **Year to 31 October 2023**
|**INVESTMENTS**
**Funds and Unit Trusts**
Holding
Book
Bid
Market
Holding
Cost or
Gain or
Prior
This
Holding
Book
Bid
Market
value
price
value
(proceeds)
loss
years
year
value
price
value
**Investments held at 31 October 2022**
**Purchases and sales**
**Resulting gains and losses**
**Investments held at 31 October 2023**
Maitland MI Twentyfour AM Dynamic Bond
I income
166
18,035
£89.11
14,761
88
(8,050)
(1,536)
(1,740)
205
78
8,450
£88.62
6,878
Polar Global Healthcare Trust
3,252
10,875
ord 25p shares
708
2,373
3,960
13,248
£2.99
11,840
Redwheel Global Horizon
55
(12,719)
(131)
(210)
80
B accumulation
110
25,700
£230.75
25,279
55
(13,177)
327
(210)
537
Schroder Asian Total Return Inv Co
ord 5 p shares
6,031
30,155
£3.85
23,197
6,031
30,155
£3.89
23,461
Stewart Invrs Asia Pacific Leaders
income units
9,686
32,000
£2.98
28,882
3,545
(10,484)
(1,228)
(1,141)
(87)
6,141
20,288
£2.81
17,276
Threadneedle UK Equity income
L Dis
13,768
16,755
£1.80
24,747
13,768
(26,993)
10,238
7,992
2,246
UK Government bonds
0.25%
8,480
8,022
8,480
8,022
£0.95
8,020
Twentyfour Absolute Return Credit
83
8,031.97
A QNG
184
19,214
£94.50
17,342
266
27,246
£96.06
25,579
UK Commerial Property REIT Ltd
ord 25 p shares
24,852
21,060
£0.62
15,491
24,852
21,060
£0.53
13,072
USD Treasury Bond 7-10 year
1,872
8,094
distribution hedged
3,608
16,260
5,480
24,353
£4.17
22,841
**Managed by Evelyn Partners**
550,403
604,783
(3,195)
26,403
20,099
6,304
585,581
611,946
**Unrealsed surplus**
_54,380_
573,611
_26,365_
**Charity Authorised Investment Funds**
Cazenove Charity Equity Value
_31-Oct_
Z income units
43,020
149,524
£4.27
183,824
43,020
149,524
£4.22
181,544
Charities Property Fund
_31-Oct_
income units
132,076
140,000
£1.46
192,383
132,076
140,000
£1.23
162,269
COIF Charities Global Equity Income Fund
_31-Oct_
income units
115,510
190,000
£2.48
286,720
115,510
190,000
£2.52
291,364
M&G Charifund
_31-Oct_
income units- yield 6.1%
10,126
144,935
£13.91
140,797
10,126
144,935
£13.75
139,209
Sarasin Endowments Fund
_6-Nov_
Class A income units
161,575
150,000
£1.10
177,732
161,575
150,000
£1.13
182,580
**Direct holding**
Worldwide Healthcare Trust Plc
_31-Oct_
ord 25 p shares
200
4,992
£33.20
6,640
1,800
2,000
4,992
£2.89
5,780
**Sub total for Charity Authorised**
**Investment funds and a direct holding**
779,451
988,096
-
-
-
-
779,451
962,746
**Totals**
1,329,855
1,592,880
(3,195)
26,403
20,099
6,304
1,365,032
1,574,692
`|**INVESTMENTS**
**Funds and Unit Trusts**
Holding
Book
Bid
Market
Holding
Cost or
Gain or
Prior
This
Holding
Book
Bid
Market
value
price
value
(proceeds)
loss
years
year
value
price
value
**Investments held at 31 October 2022**
**Purchases and sales**
**Resulting gains and losses**
**Investments held at 31 October 2023**
Maitland MI Twentyfour AM Dynamic Bond
I income
166
18,035
£89.11
14,761
88
(8,050)
(1,536)
(1,740)
205
78
8,450
£88.62
6,878
Polar Global Healthcare Trust
3,252
10,875
ord 25p shares
708
2,373
3,960
13,248
£2.99
11,840
Redwheel Global Horizon
55
(12,719)
(131)
(210)
80
B accumulation
110
25,700
£230.75
25,279
55
(13,177)
327
(210)
537
Schroder Asian Total Return Inv Co
ord 5 p shares
6,031
30,155
£3.85
23,197
6,031
30,155
£3.89
23,461
Stewart Invrs Asia Pacific Leaders
income units
9,686
32,000
£2.98
28,882
3,545
(10,484)
(1,228)
(1,141)
(87)
6,141
20,288
£2.81
17,276
Threadneedle UK Equity income
L Dis
13,768
16,755
£1.80
24,747
13,768
(26,993)
10,238
7,992
2,246
UK Government bonds
0.25%
8,480
8,022
8,480
8,022
£0.95
8,020
Twentyfour Absolute Return Credit
83
8,031.97
A QNG
184
19,214
£94.50
17,342
266
27,246
£96.06
25,579
UK Commerial Property REIT Ltd
ord 25 p shares
24,852
21,060
£0.62
15,491
24,852
21,060
£0.53
13,072
USD Treasury Bond 7-10 year
1,872
8,094
distribution hedged
3,608
16,260
5,480
24,353
£4.17
22,841
**Managed by Evelyn Partners**
550,403
604,783
(3,195)
26,403
20,099
6,304
585,581
611,946
**Unrealsed surplus**
_54,380_
573,611
_26,365_
**Charity Authorised Investment Funds**
Cazenove Charity Equity Value
_31-Oct_
Z income units
43,020
149,524
£4.27
183,824
43,020
149,524
£4.22
181,544
Charities Property Fund
_31-Oct_
income units
132,076
140,000
£1.46
192,383
132,076
140,000
£1.23
162,269
COIF Charities Global Equity Income Fund
_31-Oct_
income units
115,510
190,000
£2.48
286,720
115,510
190,000
£2.52
291,364
M&G Charifund
_31-Oct_
income units- yield 6.1%
10,126
144,935
£13.91
140,797
10,126
144,935
£13.75
139,209
Sarasin Endowments Fund
_6-Nov_
Class A income units
161,575
150,000
£1.10
177,732
161,575
150,000
£1.13
182,580
**Direct holding**
Worldwide Healthcare Trust Plc
_31-Oct_
ord 25 p shares
200
4,992
£33.20
6,640
1,800
2,000
4,992
£2.89
5,780
**Sub total for Charity Authorised**
**Investment funds and a direct holding**
779,451
988,096
-
-
-
-
779,451
962,746
**Totals**
1,329,855
1,592,880
(3,195)
26,403
20,099
6,304
1,365,032
1,574,692
`|Prior
This
years
year
**Unrealised surplus**
0%
(1,534)
(38)
-11%
-
(1,407)
1%
(6,958)
264
-4%
(1,977)
(1,036)
0%
-
(2)
1%
(1,872)
205
-16%
(5,569)
(2,419)
-9%
(1,513)|
|---|---|---|
|||34,281
4,053
1.7%
-1%
34,300
(2,280)
-16%
52,383
(30,113)
2%
96,720
4,644
-1%
(4,138)
(1,588)
3%
27,732
4,847
-13%
1,648
(860)|
||962,746|-2.6%
208,645
(25,350)|
||1,574,692|242,926
(21,297)|
**Cambridge Eye Trust**
Printed 09/05/2024
Page 11